TScan Therapeutics (TCRX) Cash & Equivalents (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Cash & Equivalents data on file, last reported at $128.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 16.9% year-over-year to $128.1 million in Q1 2026; TTM through Mar 2026 was $128.1 million, a 16.9% decrease from a year earlier, with the FY2025 full-year figure at $152.4 million, down 14.71% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $128.1 million, down from $152.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TCRX reached as high as $242.2 million in Q2 2024 and fell as low as $95.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $152.0 million across 5 years, with a median of $140.8 million in 2022.
• On a YoY basis, Cash & Equivalents climbed as much as 66.27% in 2023 and fell as far as 32.11% in 2023.
• Year by year, Cash & Equivalents stood at $120.0 million in 2022, then climbed by 11.11% to $133.4 million in 2023, then soared by 33.99% to $178.7 million in 2024, then dropped by 14.71% to $152.4 million in 2025, then retreated by 15.98% to $128.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $128.1 million in Q1 2026, $152.4 million in Q4 2025, and $169.5 million in Q3 2025.